Vericel Corporation (NASDAQ: VCEL) is a Healthcare company (Biotechnology) with a market capitalization of $3.0B. The Maz Rating grades it against the other companies in its sector.
Vericel Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $57.88, Vericel Corporation trades at 87.9x trailing earnings, 9.1x sales and 7.7x book value, with an EV/EBITDA of 59.9. Over the last twelve months it generated about $323M of revenue and $34M of net income. It runs a gross margin of 74.5%, an operating margin of 8.3% and a net margin of 10.3%. It shows return on equity of 9.1%, return on invested capital of 5.5% and a free cash flow yield of 1.6%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 5.13. Over the past 52 weeks the share price ranged from $28.95 to $59.75, with a beta of 1.06.
Vericel Corporation does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 9 Buy and 5 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Vericel Corporation (VCEL) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.7% / 30% · Interest income / Revenue 2.52% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.75% / 33% · Receivables / Mkt Cap (36m) 3.73% / 49% · Interest income / Revenue 2.52% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.75% / 33.33% · Receivables / Mkt Cap (24m) 3.73% / 33.33% · Interest income / Revenue 2.52% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 9.38% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 30.9% / 33.33% · Receivables / Avg Assets (4Q) 15.8% / 33.33% · Interest income / Revenue 2.52% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 32.9% / 33.33% · (Cash+Recv) / Total Assets 48.7% / 33.33% · Interest income / Revenue 2.52% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Vericel Corporation (VCEL) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Vericel Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.52% of each dividend: Vericel Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.